Dr. O'Donnell's research focus is on achieving individualized care by considering each patient's genetic profile when making therapeutic decisions, especially regarding different chemotherapy choices. Dr. O’Donnell has advanced training in pharmacology and pharmacogenomics, and is a well-published researcher with a number of ongoing projects including studies of genetic determinants of capecitabine susceptibility, novel early biomarkers of cisplatin nephrotoxicity, and genetic determinants of response to neoadjuvant cisplatin in patients with urothelial cancer. Dr. O'Donnell also serves as Assistant Director of The 1200 Patients Project, a new initiative within the Center for Personalized Therapeutics at the University of Chicago. In that capacity, he helps lead initiatives to explore the feasibility and utility of incorporating broad pharmacogenetic testing into routine clinical practice. He also serves as a member of the University of Chicago's Committee on Clinical Pharmacology and Pharmacogenomics, which aims to educate individuals from several subspecialties in clinical pharmacology, principle of herapeutics, molecular pharmacology and pharmacogenetics.